In this study, we assessed the efficacy and safety of ruxolitinib in controlling disease in patients with polycythaemia vera without splenomegaly who need second-line therapy.
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study / Passamonti, F., Griesshammer, M., Palandri, F., Egyed, M., Benevolo, G., Devos, T., Callum, J., Vannucchi, A.M., Sivgin, S., Bensasson, C., Khan, M., Mounedji, N., Saydam, G.. - In: THE LANCET ONCOLOGY. - ISSN 1470-2045. - ELETTRONICO. - 18:(2017), pp. 88-99. [10.1016/S1470-2045(16)30558-7]
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
VANNUCCHI, ALESSANDRO MARIA;
2017
Abstract
In this study, we assessed the efficacy and safety of ruxolitinib in controlling disease in patients with polycythaemia vera without splenomegaly who need second-line therapy.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
passamonti lanc oncol 2017.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
557.12 kB
Formato
Adobe PDF
|
557.12 kB | Adobe PDF | Richiedi una copia all'autore |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
